HPTN International Scholar ( )

Slides:



Advertisements
Similar presentations
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Advertisements

Treatment as Prevention (TasP)
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
NATIONAL INSTITUTES OF HEALTH: National Institute of Allergy and Infectious Diseases National Institute of Mental Health National Institute on Drug Abuse.
Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,
TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.
Analysis of Genetic Linkage of HIV from Couples Enrolled in the HPTN 052 Trial Susan H. Eshleman, MD/PhD HPTN Network Laboratory Johns Hopkins Univ. School.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
HIV status among discordant couples in sub-Saharan Africa: A meta-analysis involving more than 13,000 discordant couples Oghenowede Eyawo, 1 Damien de.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
Sustained Treatment as Prevention: Unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN K.H.
Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.
Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.
HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.
Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052: Summary.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.
Providing Treatment, Restoring Hope Secondary Prevention as part of HIV Clinical Care Martine Etienne, MPH, DrPH University of Maryland School of Medicine.
World Health Organization | Viet Nam Country Office1 Enhancing Benefits of Early Antiretroviral Therapy Evidence, Implication and Preliminary Findings.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels Presented by Viviane.
Paz Bailey G 1, Sternberg M 1, Puren AJ 2, Markowitz LE 1, Ballard R 1, Delany S 3, Hawkes S 4, Nwanyanwu O 1, Ryan C 1, and Lewis DA 5 1. NCHHSTP, CDC.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Elijah Odoyo-June 1,3, John Rogers 2, Walter Jaoko 1,3, Robert C. Bailey 1, 2 1 Nyanza Reproductive Health Society 2 University of Illinois at Chicago.
HPTN 073: Successful Engagement of Black MSM into a Culturally Relevant Clinical Trial for PrEP Christopher Hucks-Ortiz, MPH on behalf of the HPTN Protocol.
Correlates of being outside the cascade among adults aged years in Zimbabwe: Results from the Zimbabwe Population-based HIV.
Intervention to Reduce HIV/STI Among High-Risk Patients in China: Cluster Randomized Trial Don Operario1, Debin Wang2, Mei-Fen Yang1, Kathleen Blaney1,
Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.
Understanding time needed to link to care and start ART
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
KwaZulu-Natal, South Africa
Module 4 (e) Pregnancy and Breast Feeding
Earlier treatment and lower mortality in infants Initiating ART at
Gaps in the cascade of care in two high prevalence settings in Zimbabwe and Malawi Nolwenn Conan1, Cyrus Paye2, Erica Simons2, Abraham Mapfumo3, Tsitsi.
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
“Its Different Now”: The Changing Landscape of HIV testing
Women’s recent experience of emotional intimate partner violence is independently associated with HIV-risk behaviours: a cross-sectional study of young.
Unit 6: Second-Generation HIV/AIDS Surveillance
On behalf of The MTN-020/ASPIRE Study Team
Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,
1.
Conclusions & Implications
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
International AIDS Conference
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Richard hayes London school of hygiene & Tropical Medicine
VIEWS OF HIV PREVENTION FOR THOSE AT RISK Robinah Nakabugo, ICW EA
PrEP: A Case-by-Case Approach
Chattiya Nitpolprasert
Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana ¹Obiri-Yeboah Dorcas, School of Medical Sciences,
Seek, test and treat continuum among a cohort of injecting drug users (IDUs) and their sexual partners in HIV prevention project in Kazakhstan Assel Terlikbayeva,
The role of CD4 in patient monitoring Amsterdam July 2018
Dr. Velephi Okello, Principal Investigator, MaxART Trial
HIV/AIDS Surveillance in Europe 2011 HIV/AIDS Surveillance in Europe
Management and Development for Health (MDH)
Peter Godfrey-Faussett for Charlotte Watts
HIV.
Robert H. Remien, Co-Chair
Andreas D. Haas, PhD Postdoctoral fellow, ICAP at Columbia University
Receipt of medication-assisted treatment halves the risk of HIV-1 RNA viral load rebound for HIV-positive women who use illicit drugs Joëlla W. Adams,
Undetectable = Untransmittable
Presentation transcript:

HPTN International Scholar (2018-19) Factors associated with HIV infection in serodiscordant couples in an African setting: HPTN 052 study sub-analysis Wilfred T. Gurupira MPH HPTN International Scholar (2018-19) University of Zimbabwe College of Health Sciences – Clinical Trials Research Centre Innovation in HIV Prevention Research Workshop, 22 August 2019 Thank you for the lovely introduction. I have always been fascinated by the complexities of human behaviour especially when part of a group or as a couple. Fortunately for me, my introduction into HIV prevention clinical trials was through the 052 serodiscordant couples study. This is a study which many people in this room took part in. And it’s a study which I hope everyone knows and still remembers. To refresh your memory,

HPTN 052: Immediate vs Delayed ART for HIV Prevention in Serodiscordant Couples HIV-infected, sexually active serodiscordant couples; CD4+ cell count of the infected partner: 350-550 cells/mm3 (N = 1763 couples) Immediate HAART Initiate HAART at CD4+ cell count 350-550 cells/mm3 (n = 886 couples) Delayed HAART Initiate HAART at CD4+ cell count ≤ 250 cells/mm3* (n = 877 couples) *Based on 2 consecutive values ≤ 250 cells/mm3. Primary efficacy endpoint: virologically linked HIV transmission Primary clinical endpoints: WHO stage 4 events, pulmonary TB, severe bacterial infection and/or death Couples received intensive counseling on risk reduction and use of condoms The study sought to examine the effect of ART on preventing HIV transmission to uninfected partners in serodiscordant relationships.

HPTN 052 was a randomized clinical trial conducted across 4 continents at 13 sites in 9 countries. The results were striking.

The study found that ART had a 96% reduction in the risk of transmission to these uninfected partners. 052 firmly established HIV treatment as prevention and has been recognised as being a landmark study.

Research gap: disproportionate number of seroconversions in Africa Number of couples enrolled Number of seroconversions (linked) Africa = 954 (54%) Asia = 531 (30%) Americas = 278 (16%) TOTAL = 1763 Africa = 23 (82%) Asia = 5 Americas = (18%) TOTAL = 28 (as at interim analysis 2011) Another result that struck me was the disproportionate number of seroconversions at African sites. A little over half of the 1763 couples enrolled into the study were from African sites. Yet 82% of partner-linked seroconversions in the study were observed at these African sites. This made me wonder why?

Primary objective To identify and characterize risk factors associated with HIV infection in serodiscordant couples enrolled into the HPTN 052 study at African sites compared to non-African sites Secondary objectives: To compare serodiscordant couples across regions To compare patterns of seroconversions by region, study arm and linkage To determine factors associated with HIV infection at African sites compared to non-African sites To answer this question we conducted a secondary analysis of 052 data. The main objective was to identify and characterize risk factors associated with HIV infection in 052 serodiscordant couples at African sites as compared to non-African sites. There were three secondary objectives. First, we compared couples across regions. Second, we compared patterns of seroconversions by region, study arm and linkage. Finally we determined factors associated with HIV infection at African sites compared to non-African sites. So what did we find: When comparing couples across regions at baseline

Results: 1. Comparison of couples Similarities Age group Education level (primary and secondary) Unprotected sex (no sex or 100% condom use) Marital status (married, cohabiting) Plasma RNA viral load (>400 copies/ml) Randomization arm (immediate vs deferred) Differences (at African sites) Gender: HIV-infected females Education level (no school and post-secondary): less with no school or post-secondary school Unprotected sex (<100% condom use): reports of <less than 100% condom use # of sexual partners in past week: more reports of 3-4 encounters Plasma RNA viral load (<400 copies/ml): more participants with <400 copies/ml Type of serodiscordancy: more HIV+female, HIV-males couples we found similarities in age, education at the primary and secondary levels, reports of no sex or 100% condom use, marital status, plasma viral load greater than 400 copies per ml, and randomization arm. Differences were observed in the following: Gender – There were more HIV infected females at African sites. African sites had less participants with no school or post-secondary school There were more reports of less than 100% condom use and reports of more sexual partners in the past week at African sites. African sites had more participants with viral load less than 400 copies per ml. Finally, Due to the gender differences I mentioned earlier, there were more HIV-infected female HIV-uninfected male couples at African sites.

2. Patterns of seroconversions by region, arm and linkage Looking at the patterns of seroconversions

Taking a closer look at seroconversions at African sites alone, Incidence of any HIV-1 seroconversion (all sites): disproportionate number of seroconversions in Africa   Africa non-Africa Randomization Arm # Partner infections Incidence Rate (per 100 person years) 95% CI  All partner infections  Immediate ART therapy 16 0.75 [0.43, 1.22] 3 0.14 [0.03, 0.40] Delayed ART therapy 51 2.50 [1.86, 3.29] 8 0.37 [0.16, 0.74] Total 67 1.61 [1.24, 2.04] 11 0.25 [0.13, 0.46] Linked partner infections 2 0.09 [0.01, 0.34] 1 0.05 [0.00, 0.26] 37 1.81 [1.28, 2.50] 6 0.28 [0.10, 0.61] 39 0.93 [0.66, 1.28] 7 0.16 [0.07, 0.33] We broke down the big picture of HIV incidence to look at distribution by region, randomization arm, and we finally concentrated on the numbers indicating the differences in incidence of all seroconversions and partner-linked seroconversions. Taking a closer look at seroconversions at African sites alone,

Number of any and partner-linked HIV-1 seroconversion by site (African sites only) We observed that seroconversions were not evenly distributed among the sites. In fact two sites, Liliongwe in Malawi and Kisimu in Kenya had by far the largest number of seroconversions compared to other African sites. If we excluded data from these 2 sites, HIV incidence rates between African and non-African sites would be comparable.

3. Risk of partner infection Finally we looked at some baseline variables to determine association with HIV infection.

Cumulative hazard:

Cumulative hazard:

4. Factors associated with seroconversion Finally we looked at some baseline variables to determine association with HIV infection.

Baseline variables associated with HIV infection We found 2 that were associated with infection. The first was education status. Primary and secondary schooling was associated with HIV infection at African sites. Second, was randomization arm. Being in the deferred arm was associated with HIV infection. None of the baseline variables we looked at had any association with HIV infection at non-African sites. Bringing it all together,

Discussion Factors associated with HIV infection: Baseline CD4 count, randomization arm (delayed) and education status (primary & secondary school) Regional and in country incidence variations (Kisumu and Lilongwe; South Africa and Malawi sites) Unexplored factors: desire for children, number of children, duration of relationship, relationship dynamics To-be-explored: time varying behavioural variables e.g. outside sexual partners Two sites drove the incidence of HIV infections at African sites. Two baseline variables were associated with HIV infection. There were some factors which we could not explore, a limitation which arose as this was a secondary analysis. We would have wanted to explore desire for children, or the number of children, or duration of the serodiscordant relationship or my personal favourite, relationship dynamics Data on all these variables was not available for analysis. We are yet to explore the association between time-varying factors and HIV infection. Based on the results, and the limitations we found, we have concluded that

Conclusion Need to explore factors associated with HIV infection among African serodiscordant couples there is need to explore factors associated with HIV infection among African serodiscordant couples. It have been an interesting journey to get here.

And like Sir Isaac Newton I see further because I stand on the shoulders of giants.

SCHARP and SCHARP statisticians My CTU leadership This work is supported by the HPTN Scholars Programme which is part of the HIV Prevention Trials Network (HPTN) Mentors: Profs Taha E. Taha and James Hakim SCHARP statisticians: Jing Wang and Amber Guo UZ CHS – CTRC: Z.M. Chirenje, J. Brown, A. Markowitz HPTN International Scholars Programme team: Erica Hamilton and Gabriela Salinas-Jimenez HPTN 052 Study team All HPTN Scholars The HPTN is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068619, UM1AI068613, UM1AI1068617), with co-funding from the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health. These are my giants. My mentors SCHARP and SCHARP statisticians My CTU leadership The HPTN Scholars programme team especially Erica and Gabriela The 052 study team And my fellow Scholars past and present As I stand tall, with my head firmly in the clouds I long for the day when someone in this room at meeting just like this will announce that we have overcome the challenges of HIV prevention in serodiscordant couples. Thank you for listening!

HPTN Scholars and Mentors (June 2019) www.hptn.org/research/scholars https://twitter.com/HIVptn https://www.facebook.com/HIVptn